Clinical Trials Browser

Biliary Tract Neoplasms

Advanced KRAS Positive Metastatic Colorectal Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

Thyroid Neoplasms

Craniopharyngioma

Pancreatic Neoplasms

Uveal Melanoma, Eye Neoplasms

Brain Neoplasms, Melanoma

Lung Neoplasms

Melanoma, Skin Neoplasms

Brain Neoplasms, Melanoma

Non-small Cell Carcinoma

Gastrointestinal Stromal Tumors

Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Soft Tissue Neoplasms

Colonic Neoplasms, Colorectal Neoplasms

Brain Neoplasms, Melanoma

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms, Melanoma, Neoplasm Metastasis

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

Carcinoma, Non-Small-Cell Lung

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Advanced BRAF Mutant Cancers

Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Pancreatic Neoplasms

Melanoma, Neoplasm Metastasis

Adenocarcinoma of Lung, Pancreatic Neoplasms, Colorectal Neoplasms

Multiple Myeloma, Recurrence

Brain Neoplasms, Melanoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

Melanoma, Neoplasms

Lung Neoplasms

Colorectal Neoplasms

Gastrointestinal Stromal Tumors

Lung Neoplasms, Recurrence

Clinical Trials

SAFIR-ABC10

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

SuRage-EB

InCITe

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

BEPCOME-MB

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

BiniPembro

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

ENCO-BRAF

Study of MEK162 for Children With Low-Grade Gliomas

NeoBRAF

ENCEFALO

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

MEK162

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

EBRAIN-MEL

NF108-BINI

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

BEAVER

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

BRAF

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

SECOMBIT

QUAD01

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

CELEBRATE

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

GMMG-BIRMA

MEMBRAINS

TAILOR

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

PREMIUM

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

MErCuRIC1

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Lorlatinib Combinations in Lung Cancer